Abstract
Gene expression analyses have identified subtypes of conventional renal cell carcinoma broadly distributed into angiogenic and proliferative/ immunogenic clades. Integration with genomic and functional experiments in animal models yields an evolutionary model. Evolutionary trajectories illustrate remarkable plasticity, particularly for a tumor that typically begins with inactivation of a single gene.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Anti-Inflammatory Agents / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / genetics
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / genetics
-
Clinical Trials as Topic
-
Evolution, Molecular
-
Gene Expression Regulation, Neoplastic
-
Gene Regulatory Networks*
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / genetics
-
Mutation*
Substances
-
Angiogenesis Inhibitors
-
Anti-Inflammatory Agents
-
Antineoplastic Agents
-
Biomarkers, Tumor